T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated
immune responses. Although the crucial function of these CD4+ T cells in infection and …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic …

We developed a phenotypic screening platform for the functional exploration of dendritic
cells (DC). Here, we report a genome-wide CRISPR screen that revealed BCL2 as an …

PURPOSE The development of highly effective targeted agents for chronic lymphocytic
leukemia offers the potential for fixed-duration combinations that achieve deep remissions …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with
profound alterations and defects in the immune system and a prevalent dependency on the …

The tumor microenvironment (TME) plays an essential role in the development, growth, and
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …

Hotspot mutations in the PEST-domain of NOTCH1 and NOTCH2 are recurrently identified
in B cell malignancies. To address how NOTCH-mutations contribute to a dismal prognosis …

The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response
and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …

Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by
increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted …